Meili Sun

3.7k total citations
120 papers, 1.2k citations indexed

About

Meili Sun is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Meili Sun has authored 120 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Oncology, 42 papers in Pulmonary and Respiratory Medicine and 26 papers in Molecular Biology. Recurrent topics in Meili Sun's work include Cancer Immunotherapy and Biomarkers (24 papers), Lung Cancer Treatments and Mutations (18 papers) and Colorectal Cancer Treatments and Studies (13 papers). Meili Sun is often cited by papers focused on Cancer Immunotherapy and Biomarkers (24 papers), Lung Cancer Treatments and Mutations (18 papers) and Colorectal Cancer Treatments and Studies (13 papers). Meili Sun collaborates with scholars based in China, United States and Australia. Meili Sun's co-authors include Yuping Sun, Chuanyong Liu, Huan Shi, Jie Liu, Yihai Cao, Xianqiang Liu, Zhehai Wang, Masaki Nakamura, Lin Liu and Xing‐Mei Zhang and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Meili Sun

103 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Meili Sun China	18	588	318	293	259	152	120	1.2k
Tsutomu Iwasa Japan	23	765 1.3×	455 1.4×	539 1.8×	182 0.7×	187 1.2×	82	1.5k
Paolo Esposto Pirani Italy	15	651 1.1×	347 1.1×	124 0.4×	387 1.5×	136 0.9×	31	1.3k
Julia Gilhodes France	19	459 0.8×	513 1.6×	170 0.6×	309 1.2×	218 1.4×	38	1.2k
Anja Derer Germany	18	590 1.0×	348 1.1×	207 0.7×	611 2.4×	88 0.6×	28	1.3k
Cristian Scatena Italy	22	507 0.9×	526 1.7×	220 0.8×	170 0.7×	435 2.9×	67	1.3k
Ru Jia China	19	833 1.4×	422 1.3×	318 1.1×	415 1.6×	217 1.4×	50	1.6k
Gang Xiao China	20	376 0.6×	501 1.6×	148 0.5×	197 0.8×	209 1.4×	63	1.1k
Bohao Zheng China	19	520 0.9×	422 1.3×	241 0.8×	378 1.5×	333 2.2×	53	1.3k
Guido Giordano Italy	16	493 0.8×	267 0.8×	179 0.6×	129 0.5×	225 1.5×	76	916
Thomas Krahn Germany	18	593 1.0×	340 1.1×	215 0.7×	180 0.7×	380 2.5×	45	1.6k

Countries citing papers authored by Meili Sun

Since Specialization

Citations

This map shows the geographic impact of Meili Sun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meili Sun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meili Sun more than expected).

Fields of papers citing papers by Meili Sun

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Meili Sun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meili Sun. The network helps show where Meili Sun may publish in the future.

Co-authorship network of co-authors of Meili Sun

This figure shows the co-authorship network connecting the top 25 collaborators of Meili Sun. A scholar is included among the top collaborators of Meili Sun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Meili Sun. Meili Sun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Desai, Jayesh, Sanjeev Deva, Bo Gao, et al.. (2025). A phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti–PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation results. Cancer Chemotherapy and Pharmacology. 95(1). 99–99.

Wu, Lei, et al.. (2025). KCTD9 expression predicts immunotherapy response and enhances anti-PD-1 efficacy in colon adenocarcinoma. International Journal of Surgery. 111(10). 6755–6761.

Sun, Meili, et al.. (2025). Combining rape biochar with hydroxyapatite: An approach to reduce Cd availability and uptake in maize while enhancing bacterial abundance in alkaline contaminated soil. Applied Soil Ecology. 212. 106174–106174.

Liu, Yanan, Mingyan Zhang, Yuying Fang, et al.. (2025). Targeting JAML promotes normalization of tumour blood vessels to antagonize tumour progression via FAK/SRC and VEGF/VEGFR2 signalling pathways. Life Sciences. 368. 123474–123474. 1 indexed citations

Zhang, Chong, Mingyan Zhang, Zhenguo Wu, et al.. (2024). Metabolic score for insulin resistance predicts major adverse cardiovascular event in premature coronary artery disease. Aging. 16(7). 6364–6383. 8 indexed citations

Yu, Xianjun, Xiaofeng Zhang, J. J. Liu, et al.. (2024). 132MO Anti-claudin18.2 (CLDN18.2) antibody-drug conjugate (ADC) IBI343 in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC): Updated results from a phase I study. Annals of Oncology. 35. S1456–S1456. 2 indexed citations

Wang, Yongsheng, et al.. (2024). First-in-human phase 1 study of SPH4336, a novel cyclin-dependent kinase 4/6 inhibitor, in patients with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). e15107–e15107. 1 indexed citations

Shen, Lin, Caicun Zhou, Yinghua Ji, et al.. (2024). Results of a phase 1/2 study of MHB088C: A novel B7H3 antibody-drug conjugate (ADC) incorporating a potent DNA topoisomerase I inhibitor in recurrent or metastatic solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 3012–3012. 9 indexed citations

Gao, Chuntao, Xingyun Chen, Jihui Hao, et al.. (2024). A randomised phase 2 study of liposomal irinotecan in combination with 5-fluorouracil/leucovorin and oxalipalatin versus nab-paclitaxel plus gemcitabine in unresectable locally advanced or metastatic pancreatic cancer.. Journal of Clinical Oncology. 42(16_suppl). 4141–4141.

10.

Meng, Yanchun, Xiaojun Liu, Yuxin Mu, et al.. (2024). Phase I summary of the HB0025 efficacy and safety to the heavily pretreated non-small cell lung cancer (NSCLC) population.. Journal of Clinical Oncology. 42(16_suppl). e14600–e14600. 1 indexed citations

11.

Wang, Jie, Xiaohua Yu, Y. Hu, et al.. (2024). Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: final analysis of the randomized, phase III RATIONALE-307 trial. ESMO Open. 9(10). 103727–103727. 13 indexed citations

12.

Zheng, Xiangqian, Meiyu Fang, Yun Fan, et al.. (2024). Efficacy and safety of pralsetinib in Chinese advanced RET-mutant medullary thyroid cancer patients. Endocrine Related Cancer. 31(4). 3 indexed citations

13.

Dong, Jian, Chuan Jin, Zuoxing Niu, et al.. (2024). Iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors: A single-arm, multicenter, pivotal, phase II study.. Journal of Clinical Oncology. 42(16_suppl). 3578–3578. 1 indexed citations

14.

Yan, Peng, et al.. (2024). Reconstitution of peripheral blood T cell receptor β immune repertoire in immune checkpoint inhibitors associated myocarditis. Cardio-Oncology. 10(1). 35–35.

15.

Yu, Mengjie, et al.. (2024). An intelligent interactive system based on LLM to combine CAD API development with FEA. 1749–1755.

16.

Zhang, Xiao, Guoping Wang, Qingxia Fan, et al.. (2023). LBA79 GEMSTONE-303: Prespecified progression-free survival (PFS) and overall survival (OS) final analyses of a phase III study of sugemalimab plus chemotherapy vs placebo plus chemotherapy in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. Annals of Oncology. 34. S1319–S1319. 23 indexed citations

17.

Shen, Lin, Pei Chen, Jun Lü, et al.. (2023). 172P Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial. Annals of Oncology. 34. S1542–S1543. 6 indexed citations

18.

Zhao, Jun, Xinmin Yu, Dingzhi Huang, et al.. (2023). SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer. Journal for ImmunoTherapy of Cancer. 11(2). e006055–e006055. 15 indexed citations

19.

Wang, Jian, Ziquan Cao, Xing‐Mei Zhang, et al.. (2014). Novel Mechanism of Macrophage-Mediated Metastasis Revealed in a Zebrafish Model of Tumor Development. Cancer Research. 75(2). 306–315. 113 indexed citations

20.

Li, Fenglan, et al.. (2014). Screening of culture conditions for pathogens of potato dry rot. Acta Agriculturae Scandinavica Section B - Soil & Plant Science. 64(8). 694–699. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact